Linear poly (beta-amino ester) / mRNA / HA ternary complex, preparation method thereof and application of linear poly (beta-amino ester) / mRNA / HA ternary complex in cell transfection
Cationic polymers were solved between mRNA transfection efficiency and cytotoxicity by using linear poly(β-aminoester)/mRNA/HA ternary complex, hyaluronic acid coated with linear poly(β-aminoester) and mRNA, and mRNA, and cationic polymers were solved between mRNA transfection efficiency and cytotoxicity by using linear poly(β-aminoester)/mRNA/HA ternary complex, hyaluronic acid coated with linear poly(β-aminoester) and mRNA. The contradictions of this paper achieve efficient and safe mRNA transfection and provide an optimization strategy for cancer gene therapy.
Patent Information
- Application Number
- CN202411177047.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-12-03
AI Technical Summary
Existing nonviral messenger ribonucleic acid delivery vectors, especially cationic polymers, cannot take into account high transfection efficiency and low cytotoxicity, resulting in low mRNA transfection efficiency.
Linear poly(β-amino ester)/mRNA/HA ternary complex is used to coat linear poly(β-amino ester) and mRNA through hyaluronic acid to adjust the structure and charge of the complex to form a high transfection efficiency and Low cytotoxic vector.
It significantly improves mRNA transfection efficiency, reduces cytotoxicity, and realizes active targeting of CD44, enhances the stability and biocompatibility of the complex, and has an in vitro transfection efficiency of 92%, which is the best binary Complex transfection efficiency was 1.36 times.
Smart Images

Figure CN119061005A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedical materials, and specifically relates to a linear poly (β-amino ester) / mRNA / HA ternary complex and a preparation method thereof and application thereof in cell transfection. Background Art
[0002] Compared with viral vectors, non-viral vectors generally exhibit higher messenger RNA (mRNA) encapsulation capacity and lower immunogenicity, but their mRNA transfection efficiency is usually lower than that of viral vectors. At present, non-viral mRNA delivery vectors mainly include lipids, lipid nanoparticles (LNPs), inorganic nanoparticles and cationic polymers. Among them, LNPs have been widely studied, and significant progress has been made in optimizing cationic or ionizable lipid components and their formulations. However, LNPs also have inherent limitations. For example, most effective lipids are identified through high-throughput synthesis and screening processes, which usually involve complex and time-consuming organic synthesis and separation. In addition, small molecule lipids have limited reaction sites for further functionalization, and even slight changes in chemical structure can lead to significant differences in transfection performance.
[0003] Currently, cationic polymers, including polyethyleneimine (PEI), poly(aminoamine) (PAMAM), poly(amino acids), poly(esters), and poly(amine coesters), have been widely developed for mRNA delivery due to their ability to tightly encapsulate mRNA, promote endocytosis and endosomal escape, and are easy to synthesize. However, compared with LNPs, cationic polymers generally exhibit lower mRNA transfection efficiency. To this end, various solutions have been proposed, such as monomer combination, polymer molecular weight, topology, and end groups, or the introduction of specific components through modification. Linear poly(β-amino esters) (LPAEs) are usually synthesized by coupling amines with diacrylates under mild reaction conditions without the need for catalysis, high temperature, or high pressure. By adjusting the combination and ratio of monomers, LPAEs with different chemical compositions, topologies, amphiphilicity, molecular weights, and end groups can be synthesized, but LPAEs may have strong cytotoxicity while being accompanied by higher transfection efficiency. Summary of the invention
[0004] In order to overcome the shortcomings of the above-mentioned prior art, the purpose of the present invention is to provide an LPAE / mRNA / HA ternary complex and a preparation method thereof and an application thereof in cell transfection, so as to solve the technical problem that LPAE cannot take into account both transfection efficiency and safety.
[0005] In order to achieve the above object, the present invention adopts the following technical solutions:
[0006] In the first aspect of the present invention, a linear poly (β-amino ester) / mRNA / HA ternary complex is disclosed, which is formed by hyaluronic acid coating a linear poly (β-amino ester) and mRNA, wherein the mass ratio of the linear poly (β-amino ester) to the mRNA is (5 to 200): 1, and the mass ratio of the hyaluronic acid to the linear poly (β-amino ester) is (0.5 to 5): 1; the structural formula of the linear poly (β-amino ester) is as follows:
[0007]
[0008] Among them, n=10~40.
[0009] The second aspect of the present invention discloses a method for preparing the above-mentioned linear poly (β-amino ester) / mRNA / HA ternary complex, wherein a linear poly (β-amino ester) solution and an mRNA solution are mixed to obtain a linear poly (β-amino ester) / mRNA binary complex; and a hyaluronic acid solution and a linear poly (β-amino ester) / mRNA binary complex are mixed to obtain a linear poly (β-amino ester) / mRNA / HA ternary complex.
[0010] Preferably, the linear poly(β-amino ester) is prepared as follows:
[0011] 1) using bisphenol A glycerol ester, 2-morpholinoethylamine and dodecylamine as raw materials, through Michael addition reaction, a linear poly (β-amino ester) with a double bond at the end is obtained;
[0012] 2) When the weight average molecular weight of the linear poly(β-amino ester) with double bonds at the end is 4-5 kDa, a capping agent is added for reaction and purification to obtain the linear poly(β-amino ester).
[0013] Preferably, in step 1), the stoichiometric ratio of acrylate to amine is 1.2:1.0.
[0014] Preferably, in step 2), the end-capping agent is 3,6,9-trioxaundecane-1,11-diamine.
[0015] Preferably, in step 2), the purification step is: adding the reaction mixture to an excess mixture of diethyl ether and n-hexane under stirring conditions for reaction, then standing, taking the precipitate, and drying it.
[0016] Preferably, the linear poly(β-amino ester) is dissolved in DMSO to obtain a linear poly(β-amino ester) solution.
[0017] Preferably, hyaluronic acid is dissolved in water treated with diethyl pyrocarbonate to obtain a HA solution.
[0018] The third aspect of the present invention discloses the use of the above linear poly (β-amino ester) / mRNA / HA ternary complex in cell transfection.
[0019] The fourth aspect of the present invention discloses the use of the above-mentioned linear poly (β-amino ester) / mRNA / HA ternary complex in mRNA delivery.
[0020] Compared with the prior art, the present invention has the following beneficial effects:
[0021] The present invention provides a linear poly (β-amino ester) / mRNA / HA ternary complex, which uses hyaluronic acid to encapsulate mRNA / linear poly (β-amino ester), which can reduce cytotoxicity on the one hand, and actively target CD44 on the other hand, and enhance transfection efficiency. Using the ternary complex, the size of the complex can be increased, the Zeta potential can be reduced, and the cell uptake can be greatly enhanced. The ternary complex has the advantages of compact structure, uniform particle size distribution, good stability, biodegradability and good biocompatibility. The in vitro transfection results show that in the presence of serum, the linear poly (β-amino ester) / mRNA / HA ternary complex can achieve a transfection efficiency of up to 92% in HeLa cells while maintaining a high cell survival rate, which is 1.36 times the transfection efficiency of the best binary complex, and the use of HA pretreatment of HeLa cells will further promote the mRNA transfection of the LPAE / mRNA / HA ternary complex. It is further proved that encapsulating the LPAE / mRNA complex with natural HA is a feasible strategy to improve the mRNA transfection efficiency and safety, indicating that it can provide a simple and effective optimization strategy for cancer gene therapy. In addition, the method of packaging mRNA with natural macromolecules can be applied to other non-viral delivery vectors to achieve excellent transfection efficiency and safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 Schematic diagram of the synthesis of the linear poly (β-amino ester) of the present invention;
[0023] Figure 2 It is a GPC curve diagram of the synthesis of the linear poly (β-amino ester) of the present invention; wherein A is a monitoring curve of the weight average molecular weight of the polymer in each time period, and B is a monitoring curve of the weight average molecular weight before and after purification after stopping the reaction;
[0024] Figure 3 The linear poly (β-amino ester) of the present invention has a weight average molecular weight of 5.5 kDa. 1 HNMR spectrum;
[0025] Figure 4 is a degradation GPC curve diagram of a linear poly(β-amino ester) having a weight average molecular weight of 5.5 kDa according to the present invention;
[0026] Figure 5 The graphs show the test results of the affinity performance of DD90-C12-122 / mRNA / HA ternary complex and DD90-C12-122 / mRNA binary complex to mRNA at different mass ratios;
[0027] Figure 6 Figure 1 is a graph showing the particle size detection results of the DD90-C12-122 / mRNA / HA ternary complex and the DD90-C12-122 / mRNA binary complex at different mass ratios; wherein A is the particle size distribution curve of the ternary complex formed by HA encapsulation at different ratios when the DD90-C12-122 / mRNA mass ratio is 40:1, B is the particle size distribution curve of the ternary complex formed by HA encapsulation at different ratios when the DD90-C12-122 / mRNA mass ratio is 60:1, and C is the particle size of the DD90-C12-122 / mRNA / HA ternary complex at each ratio;
[0028] Figure 7 The Zeta potential detection results of the DD90-C12-122 / mRNA / HA ternary complex and the DD90-C12-122 / mRNA binary complex at different mass ratios are shown in the figure;
[0029] Figure 8 The microscopic morphology of the DD90-C12-122 / mRNA / HA ternary complex and the DD90-C12-122 / mRNA binary complex at different mass ratios;
[0030] Fig. 9 The fluorescence detection results of the binary complex of DD90-C12-122 / mRNA encoding GFP at different mass ratios are shown;
[0031] Fig.10 The fluorescence detection results of the DD90-C12-122 / mRNA / HA ternary complex encoding GFP at different mass ratios are shown in Figure 1; Group a and Group c are DD90-C12-122 / mRNA / HA ternary complexes encoding GFP at different ratios, and Group b and Group d are DD90-C12-122 / mRNA / HA ternary complexes encoding GFP at different ratios after being pretreated with HA for 1 hour before the transfection experiment;
[0032] Fig.11 The results of flow cytometry detection of the percentage of GFP-positive cells of DD90-C12-122 / mRNA binary complex encoding GFP at different mass ratios are shown in FIG.
[0033] Fig.12The figures are result graphs of the percentage of GFP-positive cells detected by flow cytometry of the ternary complex of DD90-C12-122 / mRNA / HA encoding GFP at different mass ratios; wherein A is a result graph of the percentage of GFP-positive cells detected by flow cytometry of the cells encapsulated with HA at different ratios to form a ternary complex when DD90-C12-122 / mRNA is 40:1, B is a result graph of the percentage of GFP-positive cells detected by flow cytometry of the cells encapsulated with HA at different ratios to form a ternary complex when DD90-C12-122 / mRNA is 60:1, and C is a bar graph of the percentage of GFP-positive cells detected by flow cytometry of the ternary complex of DD90-C12-122 / mRNA / HA at various ratios;
[0034] Fig.13 The figure is a result diagram of the average fluorescence intensity of the cell flow cytometry detection of the DD90-C12-122 / mRNA binary complex encoding GFP at different mass ratios; wherein A is a bar graph of the relative fluorescence intensity of the cell flow cytometry detection of the DD90-C12-122 / mRNA binary complex encoding GFP at different mass ratios, and B is a result diagram of the relative fluorescence intensity of the cell flow cytometry detection of the DD90-C12-122 / mRNA binary complex encoding GFP at different mass ratios;
[0035] Fig.14 The figure is the average fluorescence intensity result of cell flow cytometry detection of DD90-C12-122 / mRNA / HA ternary complex encoding GFP at different mass ratios;
[0036] Fig.15 The figure shows the cell activity detection results of the binary complex of DD90-C12-122 / mRNA encoding GFP at different mass ratios;
[0037] Fig.16 The figure shows the cell activity test results of the ternary complex of DD90-C12-122 / mRNA / HA encoding GFP at different mass ratios;
[0038] Fig.17 The graph shows the results of cell endocytosis efficiency detection of DD90-C12-122 / mRNA / HA ternary complex and DD90-C12-122 / mRNA binary complex at different mass ratios. DETAILED DESCRIPTION
[0039] In order to enable those skilled in the art to understand the characteristics and effects of the present invention, the following is a general description and definition of the terms and expressions mentioned in the specification and claims. Unless otherwise specified, all technical and scientific terms used in the text are the common meanings understood by those skilled in the art for the present invention. In the event of a conflict, the definition in this specification shall prevail.
[0040] The theories or mechanisms described and disclosed herein, whether correct or incorrect, should not limit the scope of the present invention in any way, that is, the present invention can be implemented without being limited by any specific theory or mechanism.
[0041] Herein, all features such as values, quantities, contents and concentrations defined in the form of numerical ranges or percentage ranges are for simplicity and convenience only. Accordingly, the description of numerical ranges or percentage ranges should be considered to have included and specifically disclosed all possible secondary ranges and individual values within the range (including integers and fractions).
[0042] In this document, unless otherwise specified, “includes,” “including,” “contains,” “has,” or similar terms cover the meanings of “consisting of” and “mainly consisting of,” for example, “A includes a” covers the meanings of “A includes a and other” and “A only includes a.”
[0043] In this document, in order to make the description concise, not all possible combinations of various technical features in various embodiments or examples are described. Therefore, as long as there is no contradiction in the combination of these technical features, the various technical features in various embodiments or examples can be combined arbitrarily, and all possible combinations should be considered to be within the scope of this specification.
[0044] The present invention discloses a linear poly(β-amino ester) having the following structural formula:
[0045]
[0046] Among them, n=10~40.
[0047] The present invention discloses a method for synthesizing the above linear poly(β-amino ester), comprising the following steps:
[0048] 1) using bisphenol A glycerol ester, 2-morpholinoethylamine and dodecylamine as raw materials, through Michael addition reaction, a linear poly (β-amino ester) with a double bond at the end is obtained;
[0049] Among them, the structural formula of bisphenol A glyceride is The structural formula of 2-morpholineethylamine is The structural formula of dodecylamine is
[0050] 2) When the weight average molecular weight (Mw) of the linear poly(β-amino ester) with double bonds at the end prepared in step 1) is close to 4-5 kDa, the reaction is stopped by cooling to room temperature (RT) and diluted with dimethyl sulfoxide. The linear poly(β-amino ester) with double bonds prepared in step 1) is reacted with a capping agent at room temperature (RT) for 48 hours and purified to prepare a functionalized linear poly(β-amino ester);
[0051] Wherein, the end-capping agent includes but is not limited to 3,6,9-trioxaundecane-1,11-diamine, and the structural formula of 3,6,9-trioxaundecane-1,11-diamine is The purification steps are: slowly add the reaction mixture to a mixture of excess ether and n-hexane under vigorous stirring for 5 to 20 minutes, then let it stand for 5 to 20 minutes and remove the supernatant. The precipitation process is repeated three times and the final product is dried in a vacuum oven at RT for 24 to 48 hours.
[0052] The invention discloses a linear poly (beta-amino ester) / mRNA / HA ternary complex, which is formed by hyaluronic acid (HA) coating the linear poly (beta-amino ester) and mRNA through the action of electric charge.
[0053] The present invention discloses a method for preparing a linear poly(β-amino ester) / mRNA / HA ternary complex, comprising the following steps:
[0054] 1. Preparation of linear poly(β-amino ester) / mRNA binary complex
[0055] Dissolve the linear poly(β-amino ester) in DMSO to obtain a 20 mg / mL linear poly(β-amino ester) stock solution. Dilute the linear poly(β-amino ester) stock solution and mRNA to 10 μL in sodium acetate buffer (0.025 M, pH = 5.2). Then, add the linear poly(β-amino ester) stock solution to the mRNA solution, vortex at high speed for 15 to 30 seconds, and let stand for 15 to 30 minutes to form a linear poly(β-amino ester) / mRNA binary complex;
[0056] Wherein, the mass ratio of linear poly (β-amino ester) to mRNA is (5-200):1, and linear poly (β-amino ester) includes but is not limited to:
[0057]
[0058] Among them, n=10~40.
[0059] 2. Preparation of linear poly (β-amino ester) / mRNA / HA ternary complex
[0060] HA was dissolved in water treated with diethyl pyrocarbonate (DEPC) to obtain a 12 mg / mL HA stock solution. The HA stock solution was added to the linear poly (β-amino ester) / mRNA binary complex and vortexed at high speed for 15 to 30 seconds, and allowed to stand for 15 to 30 minutes to form a linear poly (β-amino ester) / mRNA / HA ternary complex;
[0061] Among them, the mass ratio of HA to linear poly(β-amino ester) is (0.5-5):1.
[0062] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.
[0063] The following examples use conventional instruments and equipment in the art. The experimental methods in the following examples where specific conditions are not specified are usually carried out under conventional conditions or under conditions recommended by the manufacturer. The various raw materials used in the following examples are conventional commercial products unless otherwise specified, and their specifications are conventional specifications in the art. In the specification of the present invention and the following examples, unless otherwise specified, "%" represents mass percentage and ratio represents mass ratio.
[0064] 1. Preparation of Linear Poly(β-Amino Ester)
[0065] like Figure 1 As shown, bisphenol A glyceride (DD) (1192 mg, 2.46 mmol, 1.2 eq.), 2-morpholinoethylamine (90) (187 mg, 1.435 mmol, 0.7 eq.), dodecylamine (C12) (114 mg, 0.615 mmol, 0.3 eq.) and DMSO (7.5 mL) were added into a 10 mL round-bottom flask to obtain a mixture;
[0066] The stoichiometric ratio of acrylate to amine is 1.2:1.0, and the total monomer concentration of all acrylates and amines is 200 mg / mL.
[0067] The resulting mixture was stirred magnetically at 90°C. Figure 2 As shown in A, the weight average molecular weight (Mw) of the polymer was monitored by gel permeation chromatography (GPC) at various time periods (0, 2, 4, and 4.5 hours). When the Mw was 4.2 kDa, the reaction was stopped by cooling to room temperature (RT) and diluted with dimethyl sulfoxide (13.5 mL) to a final concentration of 100 mg / mL. The end-capping reagent 3,6,9-trioxaundecane-1,11-diamine (122) (576 mg, 3 mmol, 1.5 equivalents) was added and reacted at room temperature (RT) for another 48 hours, while the Mw of the polymer was monitored by GPC. The monitoring results are shown in FIG. Figure 2 As shown in B.
[0068] To purify the crude LPAE polymer, the reaction mixture was slowly added to a mixture of excess ether and n-hexane under vigorous stirring for 15 minutes, then allowed to stand for 5 minutes and the supernatant removed. The precipitation process was repeated three times. The final product was dried in a vacuum oven at RT for 24 hours while monitoring the Mw of the polymer using GPC to obtain a linear poly (β-amino ester), which was named DD90-C12-122.
[0069] like Figure 2 As shown in B, the Mw of DD90-C12-122 detected by GPC is 5.5 kDa. 1 H NMR spectrum Figure 3 As shown in the figure, the characteristic peak of methylene at 3.5 changes, confirming that 3,6,9-trioxaundecane-1,11-diamine is successfully grafted to the end of the single-chain cyclic poly (β-amino ester). The degradation GPC curve of DD90-C12-122 is shown in Figure 4 As shown, polymer DD90-C12-122 was completely degraded in 19 hours.
[0070] 2. Preparation of linear poly (β-amino ester) / mRNA binary complex
[0071] The DD90-C12-122 prepared in step 1 was dissolved in DMSO to obtain a 20 mg / mL stock solution. Based on the mass / mass (w / w) ratio of DD90-C12.122 to mRNA, the DD90-C12-12 stock solution and mRNA (purchased from TriLink, Cat. No.: EGFP mRNA-(L-7601)) was diluted to 10 μL. Subsequently, DD90-C12-122 solution was added to the mRNA solution, 50 ng or 100 ng of mRNA was used in each DD90-C12-122 solution, vortexed at high speed for 25 seconds, and allowed to stand for 25 minutes to form a stable DD90-C12-122 / mRNA binary complex.
[0072] 3. Preparation of linear poly (β-amino ester) / mRNA / HA ternary complex
[0073] HA was dissolved in water treated with diethylpyrocarbonate (DEPC) to obtain a 12 mg / mL HA stock solution. The mass / mass ratio of HA to DD90-C12-122 was then set to 0.5:1, 1:1, 3:1, and 5:1, and different amounts of HA stock solution were added to the DD90-C12-122 / mRNA binary complex prepared in step 2, followed by high-speed vortexing for 25 seconds and keeping undisturbed for 25 minutes to form a stable DD90-C12-122 / mRNA / HA ternary complex.
[0074] 4. Study on the performance of linear poly (β-amino ester) / mRNA / HA ternary complex
[0075] The DD90-C12-122 / mRNA / HA ternary complex was used as the experimental group, and the DD90-C12-122 / mRNA binary complex was used as the control group. According to the above method, DD90-C12-122 / mRNA / HA ternary complexes (DD90-C12-122:mRNA:HA=40:1:20, 40:1:40, 40:1:120, 40:1:200, 60:1:30, 60:1:60, 60:1:180 and 60:1:300) and DD90-C12-122 / mRNA binary complexes (DD90-C12-122:mRNA=20:1, 40:1, 60:1 and 80:1) of different mass ratios were prepared with 100 ng mRNA per well, and the following experiment was performed.
[0076] 1. mRNA affinity detection
[0077] Each group of DD90-C12-122 / mRNA / HA ternary complex and DD90-C12-122 / mRNA binary complex was placed in PicoGreen working solution, and the fluorescence intensity was tested to calculate the mRNA affinity efficiency.
[0078] The results are as follows Figure 5 As shown, the PicoGreen test results show that when the mass ratio is 40:1 and 60:1, the affinity efficiency of DD90-C12-122 for mRNA exceeds 95%. On this basis, the addition of HA at different mass ratios has no obvious effect on the affinity of mRNA, all reaching more than 83%, confirming that the DD90-C12-122 / mRNA / HA ternary complex has excellent affinity.
[0079] 2. Particle size and Zeta potential detection
[0080] Each group of DD90-C12-122 / mRNA / HA ternary complex and DD90-C12-122 / mRNA binary complex was placed in 1 mL of deionized water, and dynamic light scattering (DLS) was used to detect the particle size and Zeta potential.
[0081] The particle size results are as follows Figure 6 As shown, when HA is not coated, the particle size is 29nm when DD90-C12-122 / mRNA is 40:1; when DD90-C12-122 / mRNA is 60:1, the particle size is 24nm. As the HA dosage increases, the size of the DD90-C12-122 / mRNA / HA ternary complex decreases significantly. When coated with 3 to 4 times HA, the size of the DD90-C12-122 / mRNA / HA ternary complex is less than 200nm, which is close to the size of the DD90-C12-122 / mRNA binary complex. This result indicates the successful encapsulation of HA, and as the amount of HA increases, the particle size of the DD90-C12-122 / mRNA / HA ternary complex gradually decreases.
[0082] Zeta potential results are as follows Figure 7 As shown, when HA is not coated, the Zeta potential is +8.4 mV when DD90-C12-122 / mRNA is 40:1, and the Zeta potential is +21.8 mV when DD90-C12-122 / mRNA is 60:1. After HA is coated, the Zeta potential of the obtained DD90-C12-122 / mRNA / HA ternary complex changes from positive to basically negative (dropping below -20 mV). This change is caused by the adsorption of a large amount of HA on the surface of the DD90-C12.122 / mRNA binary complex.
[0083] 3. Microscopic morphology detection
[0084] Each group of DD90-C12-122 / mRNA / HA ternary complex and DD90-C12-122 / mRNA binary complex was washed with deionized water, centrifuged at high speed for 5 to 10 minutes, and then freeze-dried. Finally, the microscopic morphology of each group of complexes was observed using a transmission electron microscope (TEM).
[0085] The results are as follows Figure 8 As shown, the TEM results showed that when the DD90-C12-122 / mRNA / HA ratio was 40:1:200 and 60:1:300, the nanoparticles were compact spherical, proving that they could be stably maintained in the blood or culture medium, which was beneficial for subsequent gene transfection.
[0086] 4. Transfection efficiency and cytotoxicity test
[0087] On the basis of the different mass ratio groups, a DD90-C12-122 / mRNA binary complex control group with 50 ng of mRNA added to each well, a positive control group (LipoMax) in which cells were transfected with the commercial gene transfection reagent Lipo3000, and cells without any treatment were used as a negative control group (UT).
[0088] 1) Cell culture. 24 hours in advance, culture cells at 1.0×10 4 ~3.0×10 4 Hela cells were seeded at a density of 10 cells / well and cultured at 37°C overnight.
[0089] 2) Cell incubation: One hour before the transfection experiment, the culture medium on the cells in each well was aspirated with a pipette, and 12.5 μL of HA solution (12 mg / ml) and 87.5 μL of DMEM mixed solution containing 1% P / S and 10% FBS were added to each well and incubated for 1 hour.
[0090] 3) 80 μL of DMEM containing 1% P / S and 10% FBS was added to each group of DD90-C12-122 / mRNA / HA ternary complex and DD90-C12-122 / mRNA binary complex to dilute the solution to 100 μL.
[0091] 4) Use a pipette to aspirate the cell supernatant in each well, and then add 100 μL of DD90-C12-122 / mRNA binary complex or DD90-C12-122 / mRNA / HA ternary complex containing DMEM. Use green fluorescent protein (GFP) as a reporter gene to qualitatively and quantitatively evaluate the efficiency of gene transfection.
[0092] 5) After 24 hours of incubation, the expression of GFP was observed using a fluorescence microscope (Olympus CKX53) and the fluorescence intensity expressed in relative light units (RLU) was measured using a microplate reader (Synergy Hybrid H1, Biotek).
[0093] Fluorescence results such as Fig. 9 and Fig.10 As shown, when 100 ng mRNA was added to each well and the ratio of DD90-C12-122 to mRNA was 40:1 and 60:1, the HA encapsulation at different ratios could efficiently mediate gene transfection.
[0094] 6) After incubation for 24 hours, the efficiency of GFP mRNA transfection was tested using flow cytometry.
[0095] The results of cell flow cytometry detection of the percentage of GFP positive cells are as follows Fig.11 and Fig.12 The average fluorescence intensity of cell flow cytometry is shown in Fig.13 and Fig.14 As shown in the figure, when 100 ng mRNA was used per well, the mass ratio of DD90-C12-122 to mRNA was 40:1 and 60:1. After encapsulating different proportions of HA, they were able to efficiently mediate gene transfection, with the highest transfection efficiency reaching 92.2% and the highest relative fluorescence intensity exceeding 1.5*10 5 RLU.
[0096] 7) After incubation for 24 hours, the viability of the transfected cells was detected using the AlarmBlue kit.
[0097] The results of cell viability assay were as follows Fig.15 and Fig.16 As shown, at 100 ng of mRNA per well, when the mass ratio of DD90-C12-122 to mRNA was 40:1 and 60:1, the cell survival rates were 63.1% and 31.5%, respectively ( Fig.15 ); When the mass ratio of DD90-C12-122, mRNA and HA was 200:40:1 and 300:60:1, the cell survival rate of the unincubated group was greater than 85% ( Fig.16 ).
[0098] 5. Endocytosis efficiency detection
[0099] 24 hours before transfection, Hela cells were seeded in 96-well plates at a density of 2000 cells per well. The mRNA used was labeled with orange fluorescent (Cy3) (purchased from APEXBIO; ARCACy3 EGFP mRNA (5-moUTP)), 150 ng mRNA per well.
[0100] Gene transfection was performed according to the above steps. After 4 hours, the culture medium was removed and the cells were washed three times with PBS. Subsequently, the cells were stained with 200 μL Lysotracker Green (1 / 15000 dilution) and Hoechst33342 (0.1 mg / mL) at 37°C for 30 minutes. The cells were washed three times with PBS and observed and imaged using a fluorescence microscope (Olympus CKX53).
[0101] Test results such as Fig.17As shown, at a mass ratio of 40:1, the DD90-C12-122 / mRNA binary complex exhibited effective cellular uptake ability. After coating with 3-fold or 5-fold HA, the DD90-C12-122 / mRNA / HA ternary complex exhibited obvious aggregation within the cell, resulting in a significant increase in fluorescence intensity, especially concentrated around the nucleus. Similarly, at a mass ratio of 60:1, high fluorescence intensity was observed. When HeLa cells were pre-incubated with HA, the ternary complex did not significantly aggregate, resulting in lower fluorescence intensity.
[0102] The above contents are only for explaining the technical idea of the present invention and cannot be used to limit the protection scope of the present invention. Any changes made on the basis of the technical solution in accordance with the technical idea proposed by the present invention shall fall within the protection scope of the claims of the present invention.
Claims
1. A linear poly (β-amino ester) / mRNA / HA ternary complex, characterized in that It is formed by coating linear poly(β-amino ester) with hyaluronic acid and mRNA, the mass ratio of linear poly(β-amino ester) to mRNA is (5-200):1, and the mass ratio of hyaluronic acid to linear poly(β-amino ester) is (0.5-5):1; the structural formula of the linear poly(β-amino ester) is as follows: Among them, n=10~40.
2. The method for preparing a linear poly(β-amino ester) / mRNA / HA ternary complex according to claim 1, characterized in that: The linear poly (β-amino ester) solution and the mRNA solution are mixed to obtain a linear poly (β-amino ester) / mRNA binary complex; the hyaluronic acid solution and the linear poly (β-amino ester) / mRNA binary complex are then mixed to obtain a linear poly (β-amino ester) / mRNA / HA ternary complex.
3. The method for preparing the linear poly (β-amino ester) / mRNA / HA ternary complex according to claim 2, characterized in that: The preparation method of linear poly(β-amino ester) is as follows: 1) using bisphenol A glycerol ester, 2-morpholinoethylamine and dodecylamine as raw materials, through Michael addition reaction, a linear poly (β-amino ester) with a double bond at the end is obtained; 2) When the weight average molecular weight of the linear poly(β-amino ester) with a double bond at the end is 4-5 kDa, a capping agent is added for reaction and purification to obtain the linear poly(β-amino ester).
4. The method for preparing the linear poly (β-amino ester) / mRNA / HA ternary complex according to claim 3, characterized in that: In step 1), the stoichiometric ratio of acrylate to amine is 1.2:1.
0.
5. The method for preparing the linear poly (β-amino ester) / mRNA / HA ternary complex according to claim 3, characterized in that: In step 2), the end-capping agent is 3,6,9-trioxaundecane-1,11-diamine.
6. The method for preparing the linear poly (β-amino ester) / mRNA / HA ternary complex according to claim 3, characterized in that: In step 2), the purification step is: adding the reaction mixture to a mixture of excess ether and n-hexane under stirring conditions for reaction, then standing, taking the precipitate, and drying it.
7. The method for preparing the linear poly (β-amino ester) / mRNA / HA ternary complex according to claim 2, characterized in that: The linear poly(β-amino ester) is dissolved in DMSO to obtain a linear poly(β-amino ester) solution.
8. The method for preparing the linear poly (β-amino ester) / mRNA / HA ternary complex according to claim 2, characterized in that: Hyaluronic acid was dissolved in water treated with diethyl pyrocarbonate to obtain a HA solution.
9. Use of the linear poly (β-amino ester) / mRNA / HA ternary complex according to claim 1 in cell transfection.
10. Use of the linear poly (β-amino ester) / mRNA / HA ternary complex of claim 1 in mRNA delivery.
